<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677519</url>
  </required_header>
  <id_info>
    <org_study_id>RP-BP-EF004</org_study_id>
    <nct_id>NCT02677519</nct_id>
  </id_info>
  <brief_title>A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD</brief_title>
  <acronym>EF004</acronym>
  <official_title>A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhodes Pharmaceuticals, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhodes Pharmaceuticals, L.P.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the long-term safety and tolerability of
      methylphenidate hydrochloride extended-release capsules (Aptensio XR®) in children aged 4-5
      years who have been diagnosed with attention-deficit/hyperactivity disorder (ADHD).

      Safety and tolerability will be evaluated by assessing treatment-emergent adverse events
      (TEAEs) blood pressure, pulse, height, weight, electrocardiograms (ECGs), laboratory The
      primary objective of this study is to evaluate the long-term (12-month) safety and
      tolerability of Aptensio XR® in children aged 4 to less than 6 years who have been diagnosed
      with ADHD.

      Safety and tolerability will be evaluated by assessing treatment-emergent adverse events
      (TEAEs) blood pressure, pulse, height, weight, electrocardiograms (ECGs), laboratory values
      and Columbia Suicide Severity Rating Scale (C-SSRS). Disturbances in sleep (quantity and
      quality) patterns will also be assessed using the Child Sleep Habits Questionnaire (CSHQ).

      Secondary objectives include assessment of long-term efficacy of Aptensio XR®.

      Secondary measures include:

        -  Investigator administered Attention-Deficit/Hyperactivity Disorder Rating Scale
           Preschool Version (ADHD-RS-IV Preschool Version)

        -  Clinical Global Impressions-Severity Scale (CGI-S )

        -  Connors Early Childhood Behavior-Parent Short form [Conners EC BEH-P(S)]
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>12 month maintenance phase</time_frame>
    <description>Incidence of TEAEs during maintenance phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>12 month maintenance phase</time_frame>
    <description>Standardized assessment of suicide risk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>12 month maintenance phase</time_frame>
    <description>blood pressure, pulse, height, weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead electrocardiogram</measure>
    <time_frame>12 month maintenance phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD-RS-IV Preschool Version</measure>
    <time_frame>12 month maintenance phase</time_frame>
    <description>Investigator administered Attention-Deficit/Hyperactivity Disorder Rating Scale Preschool Version (ADHD-RS-IV Preschool Version) to assess ADHD severity and functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions-Severity Scale (CGI-S)</measure>
    <time_frame>12 month maintenance phase</time_frame>
    <description>This scale provides a global rating of illness severity and improvement during the study. The subject is rated relative to the clinician's past experience with other patients who have the same diagnosis. The CGI-S is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (among the most severely ill patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connors Early Childhood Behavior-Parent Short [ConnorsEC BEH-P(S)]</measure>
    <time_frame>12 month maintenance phase</time_frame>
    <description>Assesses behavior of preschool-aged children 2 to 6</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>10 mg Aptensio XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg methylphenidate, extended release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg Aptensio XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg methylphenidate, extended release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg Aptensio XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg methylphenidate, extended release once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg Aptensio XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg methylphenidate, extended release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg Aptensio XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg methylphenidate, extended release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg Aptensio XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg methylphenidate, extended release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg Aptensio XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg methylphenidate, extended release</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aptensio XR</intervention_name>
    <description>Orally-administered extended release formulation of methylphenidate; once daily dosing</description>
    <arm_group_label>10 mg Aptensio XR</arm_group_label>
    <arm_group_label>15 mg Aptensio XR</arm_group_label>
    <arm_group_label>20 mg Aptensio XR</arm_group_label>
    <arm_group_label>30 mg Aptensio XR</arm_group_label>
    <arm_group_label>40 mg Aptensio XR</arm_group_label>
    <arm_group_label>50 mg Aptensio XR</arm_group_label>
    <arm_group_label>60 mg Aptensio XR</arm_group_label>
    <other_name>Methylphenidate Extended Release</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects aged 4 to less than 6 years inclusive at the time consent was
             given to participate in Prior Studies. New Subjects must be at least 4 years but less
             than 6 years of age when written consent is given to participate in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Childress, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Psychiatry And Behavioral Medicine Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Kollins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry &amp; Behavioral Sciences, Duke University, Durham, NC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akwete Adjei, PhD</last_name>
    <email>akwete.adjei@pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>children</keyword>
  <keyword>methylphenidate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

